TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
BIO-TECHNE Corp
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 24, 2026
$72.49−0.08 (-0.11%)
Close on Oct 19, 2026
- Market cap
- $11.40B
- P/E (TTM)
- 62.5
- Dividend yield
- 0.44%
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
65.8%−2.2 pts over 5 years
Operating margin
20.7%−4.8 pts over 5 years
Net margin
–
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.4% | +2.2% | +5.5% | +9.3% | |
| Gross profit | +1.1% | +1.3% | +4.8% | +9.0% | |
| Operating income | +146.3% | -5.5% | +1.2% | +5.3% | |
| EPS, diluted | +152.2% | -13.0% | +5.9% | +5.2% | |
| Free cash flow | +2.6% | +6.8% | -3.1% | +7.5% | |
| Dividend per share | 0.0% | 0.0% | 0.0% | 0.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 8.3% | 9.5% | – | |
| Return on assets | 5.7% | 6.5% | – | |
| Current ratio | 2.57 | 3.35 | 4.55 | |
| Debt to equity | 0.36 | 0.22 | 0.09 | |
| Net debt to EBITDA | 1.40× | 0.44× | -0.19× | |
| Interest coverage | 16.4× | 17.0× | 26.2× | |
| Inventory turnover | 2.6× | 2.7× | 2.2× | |
| Capex to revenue | 2.7% | 4.8% | 2.4% | |
| Diluted shares | 150M | 162M | 157M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Bio-Techne generated $1.46B from operations and spent $1.04B on capital expenditure, dividends and share buybacks. 20% of that went back into the business.
Generated
$1.46B
Used
$1.04B
Capital expenditure$205.89M20%Dividends$251.20M24%Share buybacks$577.96M56%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin6.0%
×Asset turnover0.46×
×Equity multiplier1.32×
=Return on equity, FY20253.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 6.0% | 0.46× | 1.32× | 3.7% |
| FY2024 | 14.5% | 0.43× | 1.32× | 8.3% |
| FY2023 | 25.1% | 0.46× | 1.34× | 15.6% |
| FY2022 | 24.6% | 0.49× | 1.40× | 16.7% |
| FY2021 | 15.1% | 0.43× | 1.46× | 9.5% |
| FY2020 | 31.0% | 0.38× | 1.54× | 18.0% |
| FY2019 | 13.5% | 0.41× | 1.55× | 8.6% |
| FY2018 | 19.6% | 0.41× | 1.55× | 12.4% |
| FY2017 | 13.5% | 0.42× | 1.47× | 8.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
6of 6 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero$292.07M
- Return on assets improvedROA up on the prior year2.7% → –
- Earnings backed by cashOperating cash flow above net income$292.07M vs –
- Less leverageLong-term debt to assets fell13.5% → 7.7%
- Better liquidityCurrent ratio rose3.46 → 4.55
- No dilutionShare count did not rise160M → 157M
- Gross margin improvedGross margin up on the prior year64.80% → 65.77%
- More efficientAsset turnover rose0.45 → 0.48